

A Key Role for Diacylglycerol Lipase- α in Metabotropic Glutamate Receptor-Dependent Endocannabinoid Mobilization

Kwang-Mook Jung, Giuseppe Astarita, Chenggang Zhu, Matthew Wallace, Ken Mackie, and Daniele Piomelli

Departments of Pharmacology (K.-M.J., G.A., D.P.) and Biological Chemistry (C.Z., D.P.), University of California, Irvine, California; Department of Drug Discovery and Development, Italian Institute of Technology, Genova, Italy (D.P.); and Department of Anesthesiology, University of Washington, Seattle, Washington (M.W., K.M.)

Received May 4, 2007; accepted June 21, 2007

ABSTRACT

Activation of group I metabotropic glutamate (mGlu) receptors recruits the endocannabinoid system to produce both short- and long-term changes in synaptic strength in many regions of the brain. Although there is evidence that the endocannabinoid 2-arachidonoylglycerol (2-AG) mediates this process, the molecular mechanism underlying 2-AG mobilization remains unclear. In the present study, we used a combination of genetic and targeted lipidomic approaches to investigate the role of the postsynaptic membrane-associated lipase, diacylglycerol lipase type- α (DGL- α), in mGlu receptor-dependent 2-AG mobilization. DGL- α overexpression in mouse neuroblastoma Neuro-2a cells increased baseline 2-AG levels. This effect was accompanied by enhanced utilization of the 2-AG precursor 1-stearoyl,2-arachidonoyl-*sn*-glycerol and increased accumulation of the 2-AG breakdown product arachidonic acid. A similar, albeit less marked response was observed with other

unsaturated and polyunsaturated monoacylglycerols, 1,2-diacylglycerols, and fatty acids. Silencing of DGL- α by RNA interference elicited lipidomic changes opposite those of DGL- α overexpression and abolished group I mGlu receptor-dependent 2-AG mobilization. Coimmunoprecipitation and site-directed mutagenesis experiments revealed that DGL- α interacts, via a PPxxF domain, with the coiled-coil (CC)-Homer proteins Homer-1b and Homer-2, two components of the molecular scaffold that enables group I mGlu signaling. DGL- α mutants that do not bind Homer maintained their ability to generate 2-AG in intact cells but failed to associate with the plasma membrane. The findings indicate that DGL- α mediates group I mGlu receptor-induced 2-AG mobilization. They further suggest that the interaction of CC-Homer with DGL- α is necessary for appropriate function of this lipase.

The endocannabinoids are a family of lipid-derived messengers that are involved in a variety of short-range signaling events in the brain (for review, see Piomelli, 2003). Physiological experiments suggest that these lipid mediators may be released from postsynaptic neurons, diffuse across the synaptic cleft, and bind to CB₁ cannabinoid receptors on presynaptic terminals to regulate calcium and potassium

channel activities, and inhibit neurotransmitter release (for review, see Freund et al., 2003; Chevalleyre et al., 2006). This retrograde signaling process seems to be widespread in the central nervous system (CNS), but two instances of its occurrence have attracted most attention. The first is a form of short-term synaptic plasticity, termed depolarization-induced suppression of inhibition (DSI), in which depolarization of a postsynaptic cell induces the transient suppression of neurotransmitter release from GABAergic nerve terminals contacting that cell (for review, see Alger, 2002; Freund et al., 2003; Chevalleyre et al., 2006). There is ample evidence that DSI—along with its counterpart at excitatory synapses, DSE—is mediated through the Ca²⁺-dependent mobilization

This work was supported by National Institute on Drug Abuse grants DA12447 and DA12413 (to D.P.) and DA11322 and DA00286 (to K.M.).

K.-M.J. and G.A. contributed equally to this work.

Article, publication date, and citation information can be found at <http://molpharm.aspetjournals.org>.
doi:10.1124/mol.107.037796.

ABBREVIATIONS: CNS, central nervous system; DSI, depolarization-induced suppression of inhibition; 2-AG, 2-arachidonoylglycerol; PLC, phospholipase C; PIP₂, phosphatidylinositol-4,5-bisphosphate; DAG, 1,2-diacylglycerol; DGL, diacylglycerol lipase; DGL- α , diacylglycerol lipase type- α ; CC, coiled-coil; DHPG, (S)-3,5-dihydroxyphenylglycine; PCR, polymerase chain reaction; EGFP, enhanced green fluorescent protein; shRNA, small-hairpin RNA; RNAi, RNA interference; DMEM, Dulbecco's modified Eagle's medium; GFP, green fluorescent protein; DHDG, diheptadecanoyl-*sn*-glycerol; HDG, 1(3)-heptadecanoyl-*sn*-glycerol; HDA, heptadecanoic acid; mGlu, metabotropic glutamate; LC/MS, liquid chromatography/mass spectrometry; ESI, electrospray ionization; MAG, monoacylglycerol; SIM, selected ion monitoring; SAG, 1-stearoyl,2-arachidonoyl-*sn*-glycerol; HEK, human embryonic kidney; IP₃, inositol-1,4,5-trisphosphate; RHC80267, 1,6-bis(cyclohexyloximinocarbonylamino)hexane; U73122, 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione.

of an endocannabinoid messenger; however, the chemical identity of this compound remains unclear (Chevalleyre et al., 2006; Szabo et al., 2006). Another important form of endocannabinoid-mediated retrograde signaling is initiated by postsynaptic G_q -coupled receptors. In the hippocampus and other brain regions, activation of group I metabotropic glutamate receptors (mGlu1 and mGlu5) or cholinergic muscarinic receptors depresses inhibitory and/or excitatory neurotransmission, either transiently or persistently, through a CB_1 -dependent mechanism (Chevalleyre et al., 2006). This receptor-driven form of retrograde signaling is probably due to the postsynaptic release of 2-arachidonoylglycerol (2-AG).

2-AG is the most abundant endocannabinoid substance found in the mammalian CNS (Mechoulam et al., 1995; Sugiura et al., 1995; Stella et al., 1997). It is thought to be produced through phospholipase C (PLC)-catalyzed cleavage of membrane phosphatidylinositol-4,5-bisphosphate (PIP_2) to produce 1,2-diacylglycerol (DAG), followed by diacylglycerol lipase (DGL)-mediated hydrolysis of DAG to 2-AG (Scheme 1) (Stella et al., 1997). Newly produced 2-AG is broken down by monoacylglycerol lipase (Dinh et al., 2002, 2004; Muccioli et al., 2007), which is found in excitatory and inhibitory axon terminals (Gulyas et al., 2004). Electrophysiological studies have revealed that genetic deletion of type- β PLC or pharmacological inhibition of DGL activity each abrogates group I mGlu receptor-induced depression of excitatory transmission in the hippocampus (Chevalleyre and Castillo, 2003; Hashimoto et al., 2005; Maejima et al., 2005). Biochemical experiments have further demonstrated that 1) activation of group I mGlu receptors, most likely mGlu5, stimulates 2-AG formation in hippocampal and corticostriatal slice cultures and 2) PLC or DGL inhibitors prevent this response (Jung et al., 2005). Finally, electron microscopic studies have shown that type- α DGL (DGL- α)—the most abundant of the two DGL isoforms expressed in adult brain tissue (Bisogno et al., 2003)—is localized to dendritic spines of glutamatergic synapses throughout the hippocampus and cerebellum (Katz et al., 2006; Yoshida et al., 2006). It is noteworthy that DGL- α is concentrated in a perisynaptic compartment of the dendritic spine, which is also known to contain mGlu5 receptors (Luján et al., 1996, 1997).

To understand the functions served by 2-AG in retrograde signaling, it is essential to identify the molecular mechanism responsible for its mobilization. In the present study, we have combined genetic and targeted lipidomics approaches to explore the role of DGL- α in mGlu receptor-dependent 2-AG formation. Using the mouse neuroblastoma cell line Neuro-2a, which constitutively expresses mGlu5 receptors, we examined whether changes in DGL- α expression alter 2-AG mobilization and influence the cellular profile of 2-AG-related lipids. We also sought to determine whether Homer proteins containing the coiled-coil (CC) domain (Ehrengruber et al., 2004)—which are obligatory components of the postsynaptic mGlu5 receptor complex (Ango et al., 2001; Boccaert et al., 2004; Sala et al., 2005)—regulate the cellular localization and enzymatic activity of DGL- α .

Materials and Methods

Chemicals

(S)-3,5-Dihydroxyphenylglycine (DHPG) was purchased from Tocris (Ellisville, MO). Hexadecanoic acid, heptadecanoic acid

(HDA), octadecanoic acid, Δ^9 -octadecenoic acid, $\Delta^{9,12}$ -octadecadienoic acid, $\Delta^{9,12,15}$ -octadecatrienoic acid, $\Delta^{8,11,14}$ -eicosatrienoic acid, eicosatetraenoic acid, eicosapentaenoic acid, and docosahexaenoic acid were from Nu-Chek Prep (Elysian, MN); 1(3)-palmitoyl-*sn*-glycerol, 1(3)-heptadecanoyl-*sn*-glycerol (HDG), 1(3)-stearoyl-*sn*-glycerol, 1(3)-oleoyl-*sn*-glycerol, 1(3)-linoleoyl-*sn*-glycerol, 1(3)-linolenoyl-*sn*-glycerol, 1(3)-eicosatrienoyl-*sn*-glycerol, 1(3)-arachidonoyl-*sn*-glycerol, and 1(3)-docosahexaenoyl-*sn*-glycerol were from Nu-Chek Prep; 2-arachidonoyl-*sn*-glycerol and 2-linoleoyl-*sn*-glycerol were from Cayman Chemical (Ann Arbor, MI), and 2-oleoyl-*sn*-glycerol was from Sigma-Aldrich (St. Louis, MO). 1,3-Diheptadecanoyl-*sn*-glycerol (DHDG) was from Nu-Chek Prep; 1-stearoyl,2-arachidonoyl-*sn*-glycerol (SAG), 1-stearoyl,2-linoleoyl-*sn*-glycerol, 1-oleoyl,2-palmitoyl-*sn*-glycerol, 1-palmitoyl,2-stearoyl-*sn*-glycerol, 1,2-dipalmitoyl-*sn*-glycerol, and 1,2-dioleoyl-*sn*-glycerol were from Avanti Polar Lipids (Alabaster, AL). Solvents were purchased from Honeywell Burdick & Jackson (Meskegon, MI).

Plasmids

We amplified the full-length coding sequence of DGL- α by polymerase chain reaction (PCR) using High Fidelity PCR Master Mix (Roche, Indianapolis, IN) and first-strand mouse brain cDNAs as templates. We designed two primers using sequences obtained from the NCBI database (Bisogno et al., 2003): 5'-DGL- α (5'-GTTATGCCGGGATCGTGGTGTTCGG-3') and 3'-DGL- α (5'-GCGTGCAGAGATGACCAGGTCATCC-3'). The PCR product was subcloned into a pEF-V5/His vector by TOPO cloning (Invitrogen, Carlsbad, CA) to construct a mammalian expression vector encoding V5-tagged DGL- α . A construct encoding an enhanced green fluorescent protein (EGFP) fusion protein to the C-terminal of DGL- α was cloned in the pEGFP-N2 vector (Clontech, Mountain View, CA) using a SalI site. Constructs encoding Homer isoforms were cloned by PCR amplification using first-strand rat brain cDNAs as template and subsequent subcloning in pFlag-CMV vector (Stratagene, La Jolla, CA) using BamHI and EcoRI sites. The primers used were: Homer1b, 5'-GAAGGATCCATGGGGAACAACCTATCTTCAGCAC-3' (sense) and 5'-GCAGAATTCTTAGCTGCATTCTAGTAGCTTGCCAA-3' (antisense) and Homer2, 5'-GAAGGATCCATGGGAGAGCAGCCCATCTTCACC-3' (sense) and 5'-GCAGAATTCCTAGTTATCCGTGCCTAGCTTGAGGA-3' (antisense). Site-directed mutagenesis was performed using QuikChange II XL Site-Directed Mutagenesis Kit (Stratagene), following the manufacturer's instructions. The primers used were: DGL- α P975L, 5'-AATCTGGTACCCAAGCCCCCTCAGGCTCTTTGCAGGATCTG-3' (sense) and 5'-CAGATCCTGCAAAGAGCCTGAGGGGCTTGGGTACCAGATT-3' (antisense); DGL- α F978R, 5'-ACCCAAGCCCCCAGGCTCCGTGCAGGATCTGCCGAACCC-3' (sense) and 5'-GGGTTCCGCAGATCCTGCACGGAGCC-TGGGGGGCTTGGGT-3' (antisense). All constructs obtained through PCR amplifications were verified by DNA sequencing.

Cloning and Screening of shRNA Constructs

We generated small-hairpin RNA (shRNA) constructs that contained both a cytomegalovirus promoter-driven GFP and a U6 promoter-driven shRNA expression system. The shRNAs were designed using BLOCK-iT RNAi Designer (<https://rnaidesigner.invitrogen.com/rnai-express/>), and the corresponding oligonucleotides were synthesized. Sense and antisense oligonucleotides were annealed and ligated into pENTR entry vector (Invitrogen) to generate U6 promoter-shRNA-Pol III terminator cassette. The oligonucleotides used were as follows: 191i, 5'-CACCGCATCCTTCTGAGCTGTATGACGAATCATACAGCTCAG-AAGGATGC-3' (top) and 5'-AAAAGCATCCTTCTGAGCTGTATGATT-CGTCATACAGCTCAGAAGGATGC-3' (bottom); 788i (α -i), 5'-CACCGCTACAAAGAAGTCTGCTACTCGAAAGTAGCAGACTTCTTTGTAG-C-3' (top) and 5'-AAAAGCTACAAAGAAGTCTGCTACTTTCAGTAGCAGACTTCTTTGTAGC-3' (bottom); 377i, 5'-CACCGCAATGACCTCACTGCTAAGACGAATCTTAGCAGTGAGGTCATTGC-3' (top) and 5'-AAAAGCAATGACCTCACTGCTAAGATTCTGCTTAGCAGTGAG-

GTCATTGC-3' (bottom); LacZ-i, 5'-CACCGCTACACAAATCAGCGATTTCGAAAAATCGCTGATTGTGTAG-3' (top) and 5'-AAAATACACAAATCAGCGATTTTCGAAATCGCTGATTGTGTAGC-3' (bottom); Unrl-i, 5'-CACCGGATATATCCCGAACTAGACACGAATGTCTAGTTCGGGATATATCC-3' (top) and 5'-AAAAGGATATATCCCGAACTAGACATTCGTGTCTAGTTCGGGATATATCC-3' (bottom). RNAi silencing was tested by Western blotting and quantitative PCR using the pENTR constructs. Three different shRNA sequences were tested, and one was selected for further experiments. The selected shRNA expression cassette was amplified by PCR using M13F and M13R primers containing an MluI overhang at both 5' and 3' ends. The PCR product was ligated into an adeno-associated virus vector (pAAV-hrGFP; Stratagene) using MluI sites. Constructs were confirmed by DNA sequencing.

Reverse Transcriptase-PCR and Quantitative PCR

We extracted total RNA with TRIzol (Invitrogen) from Neuro-2a cells (American Type Culture Collection, Manassas, VA) cultured for 3 days after transfection, and synthesized first-strand complementary DNA using SuperScript II RNaseH reverse transcriptase (Invitrogen). Reverse transcription of total RNA (0.2 μ g) was carried out using oligo(dT)12–18 primers for 50 min at 42°C. For the identification of endogenous DGL- α mRNA, full-length DGL- α was amplified from the first-strand cDNA by using primers 5'-DGL- α (5'-GTTATGCCCGGGATCGTGGTGTTCGG-3') and 3'-DGL- α (5'-GCGTGC-CGAGATGACCAGGTCATCC-3'). Real-time quantitative PCR was conducted using an Mx3000P system (Stratagene). We designed primer/probe sets with Primer Express software (Applied Biosystems, Foster City, CA) and mouse DGL- α sequence obtained from NCBI database (GenInfo Identifier 37674270). Primers and fluorogenic probes were synthesized by TIB Molbiol (Adelphia, NJ). DGL- α mRNA levels were normalized using glyceraldehyde-3-phosphate dehydrogenase as an internal standard. The primer/probe sequences for DGL- α were: forward, 5'-CCAGGCCTTTGGGCG-3'; reverse, 5'-GCCTACCACAATCAGGCCAT-3'; and TaqMan probe, 5'-ACCTGGGCGGTGAACCAACA-3'.

Cell Transfections and Lipid Extractions

We cultured Neuro-2a cells (passage in culture: 4–20 after purchase from American Type Culture Collection) at 37°C with 5% CO₂ in Dulbecco's modified Eagle's medium (DMEM) (Invitrogen) supplemented with 10% fetal bovine serum (fetal bovine serum; Invitrogen) and antibiotics (100 unit/ml Penicillin G and 100 μ g/ml Streptomycin; Gibco-Invitrogen). We transfected cells at approximately 30% confluence using Superfect reagent (QIAGEN, Valencia, CA) and incubated them for 72 h at 37°C with 5% CO₂ in DMEM supplemented with 10% fetal bovine serum and antibiotics. In shRNA-induced silencing experiments, transfection efficiency was approximately 50%, based on GFP monitoring. We used shRNAs designed against unrelated sequences, LacZ-i and Unrl-i, as controls (Invitrogen). Cells were washed with ice-cold phosphate-buffered saline and scraped into 1 ml of methanol/water [1:1 (v/v)]. Protein concentration was measured using the BCA protein assay (Pierce, Rockford, IL). Lipids were extracted using a chloroform/methanol mixture (2:1, 1.5 ml) containing DHDG, HDG, and HDA as internal standards (100 pmol/sample). The organic phase was collected, dried under N₂ and dissolved in methanol/chloroform (3:1) for analyses. Extraction recovery efficiencies were measured from spiked biological samples compared with direct injection of nonextracted lipid standards into high-performance liquid chromatography/mass spectrometry (LC/MS): DAG, 72 \pm 5%, monoacylglycerols, 75 \pm 3%; and fatty acids, 95 \pm 2%.

Lipid Analyses

Monoacylglycerols. We used an Agilent 1100-LC system (Agilent Technologies, Palo Alto, CA) coupled to a 1946A-MS detector equipped with an electrospray ionization (ESI) interface (Agilent

Technologies). MAGs were separated on a XDB Eclipse C₁₈ column (50 \times 4.6 mm i.d., 1.8 μ m; Zorbax; Agilent Technologies). They were eluted with a gradient of methanol in water (from 85% to 90% methanol in 2.0 min and 90% to 100% in 3.0 min) at a flow rate of 1.5 ml/min. Column temperature was kept at 40°C. MS detection was in the positive ionization mode, capillary voltage was set at 3 kV, and fragmentor voltage was 120 V. N₂ was used as drying gas at a flow rate of 13 liters/min and a temperature of 350°C. Nebulizer pressure was set at 60 psi. Commercial MAGs were used as reference standards. For quantification purposes, we monitored the Na⁺ adducts of the molecular ions [M+Na]⁺ in the selected ion-monitoring (SIM) mode, using HDG (*m/z* 367) as an internal standard. Calibration curves were generated using commercial MAGs. Limit of quantification was 1.25 pmol.

Fatty Acids. We used a reversed-phase XDB Eclipse C₁₈ column (50 \times 4.6 mm i.d., 1.8 μ m; Zorbax; Agilent Technologies) eluted with a linear gradient from 90% to 100% of A in B for 2.5 min at a flow rate of 1.5 ml/min with column temperature at 40°C. Mobile phase A consisted of methanol containing 0.25% acetic acid and 5 mM ammonium acetate; mobile phase B consisted of water containing 0.25% acetic acid and 5 mM ammonium acetate. ESI was in the negative mode, capillary voltage was set at 4 kV, and fragmentor voltage was 100 V. N₂ was used as drying gas at a flow rate of 13 liters/min and a temperature of 350°C. Nebulizer pressure was set at 60 psi. We used commercially available fatty acids as reference standards, monitoring deprotonated molecular ions [M-H][−] in the SIM mode. HDA (*m/z* = 269) was the internal standard. Calibration curves were generated using commercial fatty acids. Limit of quantification was 0.5 pmol.

DAGs. We used an Agilent 1100-LC system coupled to a MS detector Ion-Trap XCT interfaced with ESI (Agilent Technologies). DAGs were separated using a reversed-phase Poroshell 300SB C₁₈ column (2.1 \times 75 mm i.d., 5 μ m; Agilent). We applied a linear gradient from 60% to 100% of mobile phase A in B in 5 min at a flow rate of 1.0 ml/min with column temperature at 30°C. Mobile phase A consisted of methanol containing 0.25% acetic acid, 5 mM ammonium acetate; mobile phase B consisted of water containing 0.25% acetic acid, 5 mM ammonium acetate. The capillary voltage was set at 4.0 kV and skimmer voltage at 40 V. N₂ was used as drying gas at a flow rate of 12 liters/min, temperature at 350°C, and nebulizer pressure at 80 psi. Helium was used as collision gas, and fragmentation amplitude was set at 1.2 V. MS detection was in the positive ionization mode. DAGs were identified based on their retention times and MS³ properties, using synthetic standards as references. Multiple reaction monitoring was used to acquire full-scan tandem MS spectra of selected DAG ions. Extracted ion chromatograms were used to quantify each DAG by selecting appropriate precursor>product ions. DHDG (*m/z* 619.8 > 349.5) was the internal standard. Calibration curves were generated using SAG. Limit of quantification was 1 pmol.

DGL Assay

We harvested Neuro-2a cells in 50 mM Tris-HCl (pH 7.0, 1 ml/dish) and homogenized them with a Dounce homogenizer on ice. Homogenates were centrifuged at 800g for 5 min at 4°C, and the resulting supernatants were used for the assay. DGL activity was measured at 37°C for 30 min in 50 mM Tris-HCl, pH 7.0, containing 0.1% Triton X-100, tissue homogenate protein (100 μ g) and DHDG (50 μ M) as substrate. The reactions were stopped by adding chloroform-methanol (1:1) containing [²H₈]-2-AG. After centrifugation at 1500g at 4°C for 5 min, the organic layers were collected and dried under N₂. The residues were suspended in chloroform/methanol (1:3, 50 μ l) and analyzed by LC/MS. For quantification purposes, we monitored the reaction product HDG [M+Na]⁺ (*m/z* 367) along with standard [²H₈]-2-AG (*m/z* 409).

Immunostaining and Western Blotting

We prepared lysates from Neuro-2a cells in a buffer containing Tris-HCl (10 mM, pH 7.4), NaCl (150 mM), Triton X-100 (1%), Nonidet P-40 (0.25%), and EDTA (2 mM) supplemented with a mixture of protease inhibitors (Roche). Lysates were centrifuged at 14,000g for 10 min. Proteins (20 μ g) from supernatants were separated by 4–20% SDS-polyacrylamide gel electrophoresis, transferred to polyvinylidene difluoride membranes, and subjected to Western blotting. We used the following antibodies: monoclonal anti-V5 (1:5000; Invitrogen), polyclonal anti-V5 (1:3000; Covance, Berkeley, CA), monoclonal anti-Flag M2 (1:3000; Sigma-Aldrich, St. Louis, MO), and polyclonal anti-DGL- α -int (1:2000; Katona et al., 2006). We cultured Neuro-2a cells on Lab-Tek chamber slides (Nalge Nunc International, Roskilde, Denmark), fixed them, and immunostained them as described previously (Jung et al., 2005), using monoclonal anti-Flag M2 (1:1000) and polyclonal anti-V5 (1:1000) as primary antibodies. Alexa 488-labeled anti-mouse or Alexa 546-labeled anti-rabbit secondary antibodies (1:1000; Invitrogen) were used for detection, which was conducted using a Eclipse E600 fluorescence microscope (Nikon, Japan) equipped with a digital camera (Diagnostic Instruments, Sterling Heights, MI).

Immunoprecipitation

We lysed the cells on ice with a buffer composed of 50 mM Tris-HCl, pH 7.0, 1 mM EDTA, 150 mM NaCl, and 1% Triton X-100 supplemented with protease inhibitor mixture (Roche). The lysates were centrifuged at 14,000g for 10 min at 4°C, and the supernatants (0.6 ml, 1 mg/ml protein) were incubated with monoclonal anti-Flag M2 antibody (1:150; Sigma-Aldrich) overnight at 4°C. The immunocomplexes were precipitated by incubation with protein G-Sepharose (40 μ l; GE Healthcare, Piscataway, NJ) for 1 h at room temperature. The immunoprecipitates were washed five times with buffer, eluted with SDS sample buffer, and analyzed by Western blotting.

Statistical Analyses

Results are expressed as means \pm S.E.M. Analyses were conducted with GraphPad Prism ver. 4.0, and differences were considered significant if $P < 0.05$ (Student's t test). For DGL- α silencing experiments shown in Fig. 3, Table 1, and Table 3, one-way analysis of variance (ANOVA) followed by Dunnett's multiple comparison test was used. Differences were considered significant if comparison with both controls gives significant changes. A representative result from at least three independent experiments was shown. N represent the number of replicates within a single experiment.

Results

DGL- α Overexpression Increases Cellular 2-AG Content. To investigate the role of DGL- α in 2-AG mobilization, we transiently overexpressed V5-His-tagged DGL- α in mouse Neuro-2a cells. We confirmed DGL- α expression using either

an anti-V5 antibody (Fig. 1A, top) or a polyclonal antibody generated against a DGL- α -GST fusion protein (Fig. 1A, middle) measuring actin as a loading control (Fig. 1A, bottom). Cells transfected with DGL- α contained significantly higher 2-AG levels than did pEF vector-transfected cells ($P < 0.001$, Student's t test) (Fig. 1B and Table 1). Levels of other unsaturated and polyunsaturated MAGs were also elevated in Neuro-2a-DGL- α cells compared with pEF vector-transfected controls (Table 1). By contrast, the cellular content of saturated MAGs remained unchanged (Table 1). It is noteworthy that MAG levels in cells transfected with either the empty pEF vector or the pEF-DGL- α vector were slightly different from those of nontransfected cells (Table 1): for example, 18:1




Fig. 1. Overexpression of DGL- α increases 2-AG levels in Neuro-2a cells. A, recombinant DGL- α expression was assessed by Western blot analysis using anti-V5 (top) or anti-DGL- α (middle) antibodies. Actin (bottom) served as a loading control. Cells were transfected with pEF6 vector (V) or DGL- α (α). B–D, effects of DGL- α overexpression on the levels of 2-AG (B), SAG (C); and unesterified stearic acid (SA) (D). See *Materials and Methods* for details of lipid measurements. *, $P < 0.05$; ***, $P < 0.001$ versus pEF, Student's t test ($n = 4$).

TABLE 1
MAG levels in Neuro-2a cells following DGL- α overexpression or silencing

MAG	DGL α Overexpression		DGL α Silencing			Nontransfected
	pEF	α	LacZ-i	Unrl-i	α -i	
	<i>pmol / mg protein</i>					
16:0 (<i>m/z</i> 353)	278 \pm 8	275 \pm 4	518 \pm 23	744 \pm 36	598 \pm 55	480 \pm 28
18:0 (<i>m/z</i> 381)	51 \pm 9	37 \pm 2	18 \pm 2	20 \pm 1	34 \pm 5	12 \pm 2
18:1 Δ^9 (<i>m/z</i> 379)	206 \pm 18	399 \pm 20***	430 \pm 12	570 \pm 48	445 \pm 23	461 \pm 18
18:2 $\Delta^{9,12}$ (<i>m/z</i> 377)	29 \pm 3	68 \pm 2***	34 \pm 3	40 \pm 3	42 \pm 7	46 \pm 6
18:3 $\Delta^{9,12,15}$ (<i>m/z</i> 375)	9 \pm 2	36 \pm 23	22 \pm 1	29 \pm 3	36 \pm 2	37 \pm 4
20:3 $\Delta^{8,11,14}$ (<i>m/z</i> 403)	59 \pm 7	166 \pm 5***	72 \pm 4	92 \pm 7	83 \pm 12	174 \pm 5
20:4 $\Delta^{5,8,11,14}$ (<i>m/z</i> 401)	322 \pm 23	1001 \pm 35***	325 \pm 22	327 \pm 24	223 \pm 19*	484 \pm 29
20:5 $\Delta^{5,8,11,14,17}$ (<i>m/z</i> 399)	12 \pm 1	34 \pm 1***	13 \pm 2	15 \pm 1	10 \pm 1	29 \pm 2
22:6 $\Delta^{4,7,10,13,16,19}$ (<i>m/z</i> 425)	10 \pm 1	23 \pm 1***	17 \pm 1	23 \pm 1	21 \pm 1	15 \pm 1

* $P < 0.05$; *** $P < 0.001$ vs. pEF, Student's t test ($n = 4$); or one-way analysis of variance followed by Dunnett's test ($n = 4$).

Δ^9 MAG was significantly lower in pEF-transfected cells than in nontransfected ones ($P < 0.001$, Student's t test). We attribute this difference, which was consistently observed in our experiments, to changes induced by transfection with the pEF vector. These minor differences notwithstanding, 2-AG levels were significantly higher in DGL- α -transfected cells than nontransfected ones ($P < 0.001$, Student's t test).

To identify the substrates used by DGL- α to produce 2-AG (Scheme 1), we profiled DAG species in Neuro-2a cells by LC coupled to an ion trap MS (LC/MSⁿ). Under our analytical conditions, most endogenous DAGs were eluted from the LC column with retention times of 5 to 6 min (Fig. 2A) and yielded informative fragmentation patterns by collision-induced dissociation of their Na⁺ adducts (Fig. 2B). Such patterns were used to identify and quantify cellular 1-acyl,2-arachidonoyl-*sn*-glycerol species, which were expected to serve as metabolic precursors for 2-AG. Significant levels of SAG were found in unstimulated Neuro-2a cells, where this DAG species accounted for approximately 84% of all 1-acyl,2-arachidonoyl-*sn*-glycerols present (Table 2). It is noteworthy that SAG content was significantly reduced in cells overexpressing DGL- α , indicating an enhanced breakdown of this 2-AG precursor (Fig. 1C).

If DGL- α cleaves SAG to generate 2-AG, unesterified stearic acid should transiently accumulate in cells. Consistent with this prediction, stearic acid levels were significantly higher in Neuro-2a-DGL- α than control cells (Fig. 1D). Other fatty acids derived from the DGL-catalyzed hydrolysis of DAGs (or from other lipolytic pathways such as the monoacylglycerol lipase-catalyzed hydrolysis of MAGs) were increased by DGL- α overexpression (Table 3). The results indicate that 1) DGL- α overexpression increase 2-AG levels in Neuro-2a cells; and 2) unstimulated Neuro-2a cells contain significant amounts of preformed DAGs, which are used by DGL- α to produce 2-AG.

DGL- α Silencing Reduced Cellular 2-AG Content. Next, to examine whether DGL- α silencing affects 2-AG mobilization, we engineered three distinct shRNAs and


screened their ability to suppress heterologous DGL- α expression in HEK293 cells. One of the shRNAs tested, 788i (α -i), produced a marked decrease in DGL- α levels (Fig. 3A). This shRNA was selected for further studies. Two control shRNAs were used, each containing an oligodeoxynucleotide sequence that is not present in the mouse or human genome. The first (LacZ-i) targeted the bacterial lacZ gene, whereas the second (Unrl-i) consisted of a random sequence of nucleotides that did not match any existing sequence in the human or mouse genome.

Neuro-2a cells constitutively express detectable, albeit low levels of DGL- α mRNA (Fig. 3B). Incubation of these cells with shRNA α -i caused a significant decrease in DGL- α mRNA (Fig. 3C). No such effect was observed in cells transfected with the two control shRNA (Fig. 3C). DGL- α silencing lowered DGL activity (Fig. 3D) and produced a set of lipidomic changes opposite those caused by DGL- α overexpression: it decreased cellular levels of 2-AG (Fig. 3E and Table 1), increased levels of the 2-AG precursor SAG (Fig. 3F), and decreased levels of unesterified stearic acid (Fig. 3G) and other fatty acids (Table 3). By contrast, no such changes in 2-AG levels were observed in Neuro-2a cells expressing control LacZ-i shRNA (Fig. 3D-G) or Unrl-i shRNA (Fig. 3E). Thus, DGL- α activity may contribute in an important way to constitutive 2-AG mobilization in Neuro-2a cells.

DGL- α Silencing Impairs mGlu Receptor-Dependent 2-AG Mobilization. Previous studies have shown that the group I mGlu receptor agonist DHPG stimulates 2-AG formation in organotypic cultures of rat brain slices (Jung et al., 2005). A similar effect was observed in Neuro-2a cells expressing control LacZ-i shRNA (Fig. 4A) as well as nontransfected cells (data not shown). Consistent with this finding, Western blot analyses demonstrated that Neuro-2a cells contained both mGlu5 receptors and PLC- β 1 (Fig. 4B). Under the same conditions, no mGlu1 receptor immunoreactivity was detected (Fig. 4B). To examine whether DGL- α participates in mGlu receptor-mediated generation of 2-AG, we tested the effects of DHPG (100 μ M) in Neuro-2a cells in which DGL- α had been silenced with shRNA α -i. DHPG did not change 2-AG content in these cells (Fig. 4A), suggesting that DGL- α is required for mGlu5 receptor-dependent 2-AG mobilization.

Subcellular Localization of DGL- α . We expressed a DGL- α -GFP fusion protein in either Neuro-2a or HEK293 cells and visualized it using fluorescence microscopy. In contrast to GFP, which was associated with the cytosol, DGL- α -GFP was primarily found on the cell surface (Fig. 5, A and B). These findings confirm previous observations indicating that DGL- α is localized to the neuronal plasma membrane (Katona et al., 2006; Yoshida et al., 2006).

DGL- α Interacts with CC-Homer Proteins. A bioinformatics search revealed that the cytoplasmic C-terminal end of DGL- α contains the PPxxF motif, which is characteristic of Homer-binding proteins such as mGlu1, mGlu5, or IP₃ receptors (Fig. 6A) (Brakeman et al., 1997; Xiao et al., 2000). To determine whether DGL- α interacts with CC-Homer proteins, we conducted coimmunoprecipitation studies in HEK293 cells that heterologously expressed DGL- α along with Homer-2 or Homer-1b. We found that DGL- α coimmunoprecipitates with either protein (Fig. 6, B and C). As previously shown for other Homer-binding proteins (Tu et al.,



Scheme 1. Proposed route for 2-AG formation and degradation in neural cells. MGL, monoacylglycerol lipase; FA, fatty acid.

1998), such coimmunoprecipitation persisted in the presence of a high concentration of the nonionic detergent Triton X-100 (1%). It is noteworthy that single point mutations of proline (P975L) and phenylalanine (F978R) in the PPxxF motif of DGL- α , which are known to prevent the interaction of group I mGlu receptors with CC-Homer (Beneken et al., 2000), abolished DGL- α /Homer-1a coimmunoprecipitation (Fig. 6C), suggesting that the two proteins interact selectively through this domain.

To determine whether Homer-2 colocalizes with DGL- α in cells, we visualized both proteins using fluorescent double-immunostaining. As illustrated in Fig. 7A, Homer-2 was associated with plasma membranes and endoplasmic-like structures in the cytosol. Merged images showed that DGL- α was localized to plasma membranes together with Homer-2 (Fig. 7A). In contrast, the DGL- α mutant P975L, which is unable to bind Homer (Fig. 6C), remained associated with intracellular structures (Fig. 7A).

We next asked whether CC-Homer proteins affect the ability of DGL- α to mobilize 2-AG in intact cells. Coexpression of DGL- α with Homer-1b or Homer-2 produced only small increases in cellular 2-AG content that were not affected by the P975L mutation (Fig. 7B). We interpret these results to indicate that, in our heterologous expression system, the interaction of CC-Homer with DGL- α is required for the membrane localization of this lipase, but not for its enzymatic activity.

Discussion

Group I mGlu receptors regulate excitatory transmission throughout the CNS by releasing a diffusible signal that leaves the dendritic spine, crosses the synaptic cleft, and activates CB₁ cannabinoid receptors on adjacent glutamatergic axon terminals (for review, see Chevalleyre et al., 2006). Although biochemical and pharmacological evidence suggests that 2-AG may be the messenger—or at least one of the messengers—responsible for this receptor-operated retrograde signaling process (Jung et al., 2005; Maejima et al., 2005), many aspects of the molecular mechanism governing 2-AG mobilization remain unknown. The present findings identify DGL- α , a serine lipase localized to the plasma membrane of glutamatergic dendritic spines (Bisogno et al., 2003; Katona et al., 2006; Yoshida et al., 2006), as a key component of the enzymatic machinery responsible for mGlu receptor-dependent 2-AG mobilization. The results further show that DGL- α selectively interacts with the CC-Homer proteins Homer-1b and Homer-2.

Group I mGlu receptors, consisting of the mGlu 1 and mGlu 5 subtypes, are G_q-coupled receptors that are concentrated in the perisynaptic compartment of glutamatergic dendritic spines (Nusser et al., 1994; Luján et al., 1996, 1997). They stimulate PLC- β to cleave membrane PIP₂ and produce inositol-1,4,5-trisphosphate (IP₃)—which binds to IP₃ receptors and triggers calcium release from intracellular




Fig. 2. Identification of 1-acyl,2-arachidonoyl-*sn*-glycerol species in Neuro-2a cells. Representative LC chromatogram (A) and mass spectra (B) of cell-derived 1-stearoyl,2-arachidonoyl-*sn*-glycerol.

TABLE 2
Molecular composition of 1-acyl-2-arachidonoyl-*sn*-glycerol species in nontransfected Neuro-2a cells, as assessed by ion-trap LC/MSⁿ analysis

Acyl Group in <i>sn</i> -1	Precursor Ion [MNa] ⁺	Product Ion [M-R ₂ COOH] ⁺	[DAG]	Proportion
	<i>m/z</i>	<i>m/z</i>	<i>nmol/mg protein</i>	<i>% moles</i>
18:0	667.8	341.5	8.8 ± 1.5	82
18:1	665.8	339.5	1.2 ± 0.5	11
16:0	639.8	313.5	0.53 ± 0.06	5
22:6	711.8	385.5	0.11 ± 0.02	1
20:4	687.8	361.5	0.085 ± 0.003	0.8
14:0	611.8	285.5	0.021 ± 0.003	0.2
18:2	Trace	Trace		Trace

TABLE 3
Unesterified fatty acid levels in Neuro-2a cells after DGL-α overexpression or silencing

Fatty Acid	DGLα Overexpression		DGLα Silencing			Nontransfected
	pEF	α	LacZ-i	Unrl-i	α-i	
	<i>pmol/mg protein</i>					
16:0 (<i>m/z</i> 255)	293 ± 7	311 ± 11	149 ± 3	157 ± 5	140 ± 3	129 ± 4
18:0 (<i>m/z</i> 283)	414 ± 19	487 ± 9*	243 ± 5	245 ± 10	220 ± 7	262 ± 7
18:1 Δ ⁹ (<i>m/z</i> 281)	158 ± 1	211 ± 6***	127 ± 4	129 ± 3	96 ± 3**	121 ± 7
18:2 Δ ^{9,12} (<i>m/z</i> 279)	10 ± 1	13 ± 0.2*	8.0 ± 0.3	6.6 ± 0.3	5.1 ± 0.2**	5.5 ± 0.3
18:3 Δ ^{9,12,15} (<i>m/z</i> 277)	0.8 ± 0.1	0.7 ± 0.1	0.4 ± 0.0	0.4 ± 0.0	0.3 ± 0.0	0.3 ± 0.0
20:3 Δ ^{8,11,14} (<i>m/z</i> 305)	3.5 ± 0.1	4.8 ± 0.2**	3.5 ± 0.2	3.3 ± 0.1	2.4 ± 0.2*(*)	3.0 ± 0.2
20:4 Δ ^{5,8,11,14} (<i>m/z</i> 303)	11 ± 0.5	19 ± 0.7***	10 ± 0.6	7.7 ± 0.3	5.8 ± 0.4*(*)	6.4 ± 0.5
20:5 Δ ^{5,8,11,14,17} (<i>m/z</i> 301)	3.7 ± 0.4	4.8 ± 0.3	2.5 ± 0.1	2.2 ± 0.1	2.6 ± 0.1	7.2 ± 0.6
22:6 Δ ^{4,7,10,13,16,19} (<i>m/z</i> 327)	0.5 ± 0.0	0.3 ± 0.0	0.2 ± 0.0	0.2 ± 0.0	0.3 ± 0.0	0.3 ± 0.0

* *P* < 0.05; ** *P* < 0.01; *** *P* < 0.001 vs. pEF, Student's *t* test (*n* = 4); or one-way analysis of variance followed by Dunnett's test (*n* = 4).




Fig. 3. RNAi-induced silencing of DGL-α in Neuro-2a cells. A, effects of various shRNAs on DGL-α levels in HEK293 cells expressing recombinant DGL-α-V5. Cells were harvested 72 h after transfection, and DGL-α expression was monitored by Western blot analysis using an anti-V5 antibody. B, representative RT-PCR demonstrating the presence of DGL-α mRNA in Neuro-2a cells. N, Neuro-2a cells; C, mouse brain. C and D, effects of DGL-α silencing on the level of DGL-α (C) and DGL (D) activity in Neuro-2a cells treated with control shRNA (LacZ-i and Unrl-i) or DGL-α shRNA (α-i). E–G, effects of DGL-α silencing on levels of 2-AG (E), SAG (F), and unesterified stearic acid (SA) (G). *, *P* < 0.05; **, *P* < 0.01 versus LacZ-i, Student's *t* test (*n* = 4).

activity, decreases baseline 2-AG levels, and abrogates group I mGlu-dependent 2-AG mobilization. These results are consistent with previous studies showing that the DGL inhibitor RHC80267 prevents mGlu5-induced 2-AG formation (Jung et al., 2005) and indicate that DGL- α may be responsible for the release of this endocannabinoid messenger. Moreover, our immunoprecipitation experiments show that DGL- α selectively interacts with CC-Homer proteins. This interaction seems to be functionally important, in that single-nucleotide

mutations that prevent DGL- α binding to CC-Homer also disrupt the localization of DGL- α to the plasma membrane. Although we used a transfected cell line to test our hypothesis, this result acquires significance in light of the neuro-anatomical distribution of DGL- α , which is localized to the same presynaptic compartment of the dendritic spine that contains the group I mGlu receptor complex (Nusser et al., 1994; Luján et al., 1996, 1997; Katona et al., 2006; Yoshida et al., 2006). A functional association of mGlu receptors with DGL- α would enable this lipase to become rapidly activated in response to receptor occupation, and generate significant amounts of 2-AG in close proximity to presynaptic CB₁ receptors (Katona et al., 2006; Yoshida et al., 2006). Furthermore, the localization of DGL- α may account for the differential contribution of mGlu5 and muscarinic acetylcholine receptor to endocannabinoid-mediated plasticity, as recently observed at synapses of striatal medium spiny neurons (Uchigashima et al., 2007).

The LC/MSⁿ analyses conducted here, which included several key substrates and products of DGL- α -catalyzed DAG hydrolysis, allowed us to obtain a broad view of the lipidomic changes induced by DGL- α overexpression or silencing. Two noteworthy points emerge from these analyses. First, unsaturated MAGs, such as 2-AG and, to a minor extent, 2-oleoylglycerol, are the primary products of DGL- α activity in intact cells. This product selectivity, which was not observed in broken cell preparations (Bisogno et al., 2003), may result from the availability in intact Neuro-2a cells of substrate DAG species containing arachidonic and oleic acid at the *sn*-2 position. Second, unstimulated Neuro-2a cells contain significant amounts of preformed DAGs, such as SAG, which may serve as 2-AG precursors. In separate experiments, we have also found high SAG levels in various regions of snap-frozen rat brain, including the amygdala (6.6 ± 0.3 nmol/g; $n = 3$) and the cerebellum (0.6 ± 0.02 nmol/g; $n = 3$) (G. Astarita and D. Piomelli, unpublished observations), where SAG is presumably derived from PIP₂ hydrolysis (Wenk et al., 2003). These results suggest that elevation in intracellular Ca²⁺ levels in dendritic spines might initiate 2-AG mobilization through a direct activation of DGL- α , rather than through a traditional route involving the sequential activation of PLC- β and DGL- α . Consistent with this possibility, electrophysiological experiments have shown that DHPG-induced sup-




Fig. 4. DGL- α silencing attenuates mGlu receptor-dependent 2-AG mobilization. A, 2-AG levels in control (LacZ-i) or DGL- α -silenced (α -i) Neuro-2a cells incubated with fresh media containing vehicle (open bars) or DHPG (100 μ M) (closed bars) for 5 min at 37°C ($n = 6$). **, $P < 0.01$; ***, $P < 0.001$. B, Western blot analysis showing the presence of mGlu5 receptor and PLC- β immunoreactivity in extracts of Neuro-2a cells. mGlu1 receptor was not detectable by this method.




Fig. 5. Recombinant DGL- α localizes to the plasma membrane and endoplasmic-like structures in Neuro-2a cells (A) or HEK293 cells (B). Forty-eight hours after transfection with DGL- α -pEGFP or pEGFP, cells were fixed and the nuclei were stained with 4,6-diamidino-2-phenylindole (blue). Images are representative of two separate experiments.

A

cDNA	Sequence
DGL α -Human	KPPRLFAG (971-978)
-Mouse	KPPRLFAG (973-980)
-Rat	KPPRLFAG (973-980)
mGluR1aR (r)	TPSPFRD (1145-1152)
mGluR5R (r)	TPSPFRD (1123-1130)
IP3R (h)	NPPKKFRD (48-55)
RyR (h)	RPPHHFSA (1771-1778)

C




Fig. 6. DGL- α interacts with CC-Homer proteins. A, the C-terminal cytoplasmic tail of human (h), mouse (m), and rat (r) DGL- α contains the Homer-binding motif PPxxF. B, DGL- α immunoprecipitates with Homer-2. Lysates of HEK293 cells transfected with V5-tagged DGL- α and Flag-tagged Homer-2 were incubated with an anti-Flag antibody and the resulting immunoprecipitates (IP) were analyzed by Western blotting using an anti-V5 antibody to visualize DGL- α , or an anti-Flag antibody to visualize Homer-2. Immunoprecipitation of Homer by the Flag antibody causes coimmunoprecipitation of DGL- α (center lane). Input shows that identical amounts of protein were provided for the immunoprecipitation in the first two lanes. C, effects of point mutations in the PPxxF Homer-binding motif of DGL- α (P975L and F978R) on its ability to immunoprecipitate with Homer-1b.




Fig. 7. Interaction with CC-Homer proteins is required for the cell membrane localization of DGL- α . **A**, localization of DGL- α and Homer-2 in Neuro-2a cells. Cells were stained using anti-Flag to visualize Flag-Homer2 (green) and anti-V5 antibody to visualize DGL- α -V5 (red). 4,6-Diamidino-2-phenylindole was used to stain nuclei (blue). **B**, levels of 2-AG were measured in Neuro-2a cells coexpressing indicated DGL- α and Homer proteins. V, pCMV Vector; H1b, Homer 1b; H2, Homer2. *, $P < 0.05$; **, $P < 0.01$ versus pCMV vector, Student's t test ($n = 6$).

pression of inhibition in the hippocampus and DSI in the cerebellum is inhibited by the DGL inhibitors RHC80267 and tetrahydrolipstatin but is not affected by the PLC inhibitor U73122 (Edwards et al., 2006; Szabo et al., 2006).

Our experiments have not addressed the possible functions served by DGL- β , a second DGL isoform present in the mammalian CNS (Bisogno et al., 2003). Clear developmental and structural differences exist between these two isoforms (Bisogno et al., 2003). It is noteworthy that DGL- β lacks the CC-Homer-binding motif present in DGL- α and, when expressed in Neuro-2a cells, it associates with intracellular structures rather than with the plasma membrane (K.-M. Jung and D. Piomelli, unpublished observations). However, the significance of these differences to neuronal 2-AG mobilization remains to be determined. This question notwithstanding, the present results provide new evidence for a primary role of DGL- α in mGlu5 receptor-dependent 2-AG mobilization and highlight the value of targeted lipidomic analyses in the study of brain endocannabinoid signaling.

Acknowledgments

We thank Dr. Faizy Ahmed for helpful discussion and Christopher Stapleton and Mariam Behbehani for their invaluable experimental help. The contribution of the Agilent Technologies/University of California, Irvine Analytical Discovery Facility, Center for Drug Discovery is gratefully acknowledged.

References

- Alger BE (2002) Retrograde signaling in the regulation of synaptic transmission: focus on endocannabinoids. *Prog Neurobiol* 68:247–286.
 Ango F, Prezeau L, Muller T, Tu JC, Xiao B, Worley PF, Pin JP, Bockaert J, and Fagni L (2001) Agonist-independent activation of metabotropic glutamate receptors by the intracellular protein Homer. *Nature* 411:962–965.

- Beneken J, Tu JC, Xiao B, Nuriya M, Yuan JP, Worley PF, and Leahy DJ (2000) Structure of the Homer EVH1 domain-peptide complex reveals a new twist in polyproline recognition. *Neuron* 26:143–154.
 Bisogno T, Howell F, Williams G, Minassi A, Cascio MG, Ligresti A, Matias I, Schiano-Moriello A, Paul P, Williams EJ, et al. (2003) Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. *J Cell Biol* 163:463–468.
 Bockaert J, Dumuis A, Fagni L, and Marin P (2004) GPCR-GIP networks: a first step in the discovery of new therapeutic drugs? *Curr Opin Drug Discov Devel* 7:649–657.
 Brakeman PR, Lanahan AA, O'Brien R, Roche K, Barnes CA, Hagan RL, and Worley PF (1997) Homer: a protein that selectively binds metabotropic glutamate receptors. *Nature* 386:284–288.
 Chevalere V and Castillo PE (2003) Heterosynaptic LTD of hippocampal GABAergic synapses: a novel role of endocannabinoids in regulating excitability. *Neuron* 38:461–472.
 Chevalere V, Takahashi KA, and Castillo PE (2006) Endocannabinoid-mediated synaptic plasticity in the CNS. *Annu Rev Neurosci* 29:37–76.
 Dinh TP, Carpenter D, Leslie FM, Freund TF, Katona I, Sensi SL, Kathuria S, and Piomelli D (2002) Brain monoglyceride lipase participating in endocannabinoid inactivation. *Proc Natl Acad Sci U S A* 99:10819–10824.
 Dinh TP, Kathuria S, and Piomelli D (2004) RNA interference suggests a primary role for monoacylglycerol lipase in the degradation of the endocannabinoid 2-arachidonoylglycerol. *Mol Pharmacol* 66:1260–1264.
 Edwards DA, Kim J, and Alger BE (2006) Multiple mechanisms of endocannabinoid response initiation in hippocampus. *J Neurophysiol* 95:67–75.
 Ehrenguber MU, Kato A, Inokuchi K, and Hennou S (2004) Homer/Vesl proteins and their roles in CNS neurons. *Mol Neurobiol* 29:213–227.
 Freund TF, Katona I, and Piomelli D (2003) Role of endogenous cannabinoids in synaptic signaling. *Physiol Rev* 83:1017–1066.
 Gulyas AI, Cravatt BF, Bracey MH, Dinh TP, Piomelli D, Boscia F, and Freund TF (2004) Segregation of two endocannabinoid-hydrolyzing enzymes into pre- and postsynaptic compartments in the rat hippocampus, cerebellum and amygdala. *Eur J Neurosci* 20:441–458.
 Hashimoto Tani Y, Ohno-Shosaku T, Tsubokawa H, Ogata H, Emoto K, Maejima T, Araishi K, Shin HS, and Kano M (2005) Phospholipase C β 2 serves as a coincidence detector through its Ca^{2+} dependency for triggering retrograde endocannabinoid signal. *Neuron* 45:257–268.
 Hofmann T, Obukhov AG, Schaefer M, Harteneck C, Gudermandt T, Schultz (1999) Direct activation of human TRPC6 and TRPC3 channels by diacylglycerol. *Nature* 397:259–263.
 Jung KM, Mangieri R, Stapleton C, Kim J, Fegley D, Wallace M, Mackie K, and Piomelli D (2005) Stimulation of endocannabinoid formation in brain slice cultures through activation of group I metabotropic glutamate receptors. *Mol Pharmacol* 68:1196–1202.
 Katona I, Urban GM, Wallace M, Ledent C, Jung KM, Piomelli D, Mackie K, and Freund TF (2006) Molecular composition of the endocannabinoid system at glutamatergic synapses. *J Neurosci* 26:5628–5637.
 Kim SJ, Kim YS, Yuan JP, Petralia RS, Worley PF, and Linden DJ (2003) Activation of the TRPC1 cation channel by metabotropic glutamate receptor mGluR1. *Nature* 426:285–291.
 Luján R, Nussler Z, Roberts JD, Shigemoto R, and Somogyi P (1996) Perisynaptic location of metabotropic glutamate receptors mGluR1 and mGluR5 on dendrites and dendritic spines in the rat hippocampus. *Eur J Neurosci* 8:1488–1500.
 Luján R, Roberts JD, Shigemoto R, Ohishi H, and Somogyi P (1997) Differential plasma membrane distribution of metabotropic glutamate receptors mGluR1 α , mGluR2 and mGluR5, relative to neurotransmitter release sites. *J Chem Neuroanat* 13:219–241.
 Maejima T, Oka S, Hashimoto T, Ohno-Shosaku T, Aiba A, Wu D, Waku K, Sugiura T, and Kano M (2005) Synaptically driven endocannabinoid release requires Ca^{2+} -assisted metabotropic glutamate receptor subtype 1 to phospholipase C β 2 signaling cascade in the cerebellum. *J Neurosci* 25:6826–6835.
 Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, Gopher A, Almog S, Martin BR, Compton DR, et al. (1995) Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. *Biochem Pharmacol* 50:83–90.
 Muccioli GG, Xu C, Odah E, Cudaback E, Cisneros JA, Lambert DM, Lopez Rodriguez ML, Bajjalieh S, and Stella N (2007) Identification of a novel endocannabinoid-hydrolyzing enzyme expressed by microglial cells. *J Neurosci* 27:2883–2889.
 Nussler Z, Mulvihill E, Streit P, and Somogyi P (1994) Subsynaptic segregation of metabotropic and ionotropic glutamate receptors as revealed by immunogold localization. *Neuroscience* 61:421–427.
 Piomelli D (2003) The molecular logic of endocannabinoid signalling. *Nat Rev Neurosci* 4:873–884.
 Sala C, Roussignol G, Meldolesi J, and Fagni L (2005) Key role of the postsynaptic density scaffold proteins Shank and Homer in the functional architecture of Ca^{2+} homeostasis at dendritic spines in hippocampal neurons. *J Neurosci* 25:4587–4592.
 Szabo B, Urbanski MJ, Bisogno T, Di Marzo V, Mendiguen A, Bar W, and Freiman I (2006) Depolarization-induced retrograde synaptic inhibition in the cerebellar cortex is mediated by 2-arachidonoylglycerol. *J Physiol* 577:263–280.
 Stella N, Schweitzer P, and Piomelli D (1997) A second endogenous cannabinoid that modulates long-term potentiation. *Nature* 388:773–778.
 Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K, Yamashita A, and Waku K (1995) 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. *Biochem Biophys Res Commun* 215:89–97.
 Tu JC, Xiao B, Yuan JP, Lanahan AA, Leoffert K, Li M, Linden DJ, and Worley PF (1998) Homer binds a novel proline-rich motif and links group 1 metabotropic glutamate receptors with IP3 receptors. *Neuron* 21:717–726.
 Uchigashima M, Narushima M, Fukaya M, Katona I, Kano M, and Watanabe M

- (2007) Subcellular arrangement of molecules for 2-arachidonoyl-glycerol-mediated retrograde signaling and its physiological contribution to synaptic modulation in the striatum. *J Neurosci* **27**:3663–3676.
- Wenk MR, Lucast L, Di Paolo G, Romanelli AJ, Suchy SF, Nussbaum RL, Cline GW, Shulman GI, McMurray W, De Camilli P (2003) Phosphoinositide profiling in complex lipid mixtures using electrospray ionization mass spectrometry. *Nat Biotechnol* **21**:813–817.
- Xiao B, Tu JC, and Worley PF (2000) Homer: a link between neural activity and glutamate receptor function. *Curr Opin Neurobiol* **10**:370–374.
- Yoshida T, Fukaya M, Uchigashima M, Miura E, Kamiya H, Kano M, and Watanabe

M (2006) Localization of diacylglycerol lipase- α around postsynaptic spine suggests close proximity between production site of an endocannabinoid, 2-arachidonoyl-glycerol, and presynaptic cannabinoid CB1 receptor. *J Neurosci* **26**:4740–4751.

Address correspondence to: Dr. Daniele Piomelli, Department of Pharmacology, 3101 Gillespie NRF, University of California, Irvine, CA 92697-4625. E-mail: piomelli@uci.edu
